Medigene

08.03.2022 • News

BioNTech and Medigene Collaborate on Cancer Therapy

Two German biotechs, RNA vaccines specialist BioNTech and Medigene, a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, have entered a three-year multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.

Top-Feature

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Free Virtual Event

Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.